ReviewBioscience reports2025
Potential role of polydatin in treating diabetes mellitus and diabetes-related chronic complications.
Review in Bioscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a complex metabolic disorder associated with severe complications affecting various organs, including the kidneys, nerves, heart, and blood vessels. Managing these complications remains a significant clinical challenge, necessitating the exploration of novel therapeutic approaches. This review focuses on polydatin, a naturally occurring glycoside from Polygonum cuspidatum, highlighting its potential as a multitargeted therapeutic agent against diabetic complications. Evidence indicates that polydatin effectively improves insulin sensitivity, lowers blood glucose levels, and exhibits antioxidant properties. In diabetic nephropathy, polydatin has been shown to reduce oxidative stress, inflammation, and podocyte apoptosis, thereby preserving renal function. Furthermore, it enhances mitochondrial function and Sirt1 expression in diabetic neuropathy, promoting nerve regeneration and alleviating pain. In cardiac studies, polydatin protects against diabetic cardiomyopathy by enhancing autophagy and reducing oxidative stress, ultimately improving cardiac function. Additionally, polydatin restores endothelial function in vascular complications associated with diabetes. Polydatin presents a promising natural therapy with the potential to mitigate multiple complications of diabetes through its antioxidant, anti-inflammatory, and cytoprotective effects. Although findings from animal models and in vitro studies are promising, further clinical research is essential to validate its efficacy and safety in human subjects. By integrating polydatin into diabetes management strategies, there is potential for improved health outcomes and quality of life for individuals affected by this chronic condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.